NCT01508208

Brief Summary

The presence of proteinuria (\>300 mg/d) represents an important factor in the diagnosis and evaluation of the pregnant patient with an hypertensive disorder. The 24 hour collection of urine for proteinuria is the gold standard for the diagnosis of the condition and allows the physician to determine if an hypertensive disorder is related directly or not to the gestation. The problem is the time it takes and the technical difficulties related to the sample collection. An alternative is the quantification of protein and creatinine in a random sample of urine. We seek to evaluate if this method is as affective as the gold standard in the diagnosis of proteinuria (\>300 mg/d).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
420

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Mar 2012

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 8, 2012

Completed
3 days until next milestone

First Posted

Study publicly available on registry

January 11, 2012

Completed
2 months until next milestone

Study Start

First participant enrolled

March 1, 2012

Completed
4.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2016

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2016

Completed
Last Updated

January 4, 2018

Status Verified

January 1, 2018

Enrollment Period

4.3 years

First QC Date

January 8, 2012

Last Update Submit

January 2, 2018

Conditions

Keywords

Hypertension24 hour urine proteinProtein/creatinine ratio

Outcome Measures

Primary Outcomes (1)

  • Sensitivity and Specificity

    The number of patients with a 24 hour urine collection with a proteinuria \> 300mg will be compared with the number of patients with a Spot Test (protein/creatinine ratio in a random urine sample) \> 0.2 (equivalent to the 24 hour test \> 300 mg). This value will be used to calculate the Sensitivity and Specificity of the spot test.

    Six months

Secondary Outcomes (1)

  • Positive and Negative Predictive Value

    six months

Study Arms (1)

Hypertensive disorder of pregnancy

OTHER

Patients with an hypertensive disorder of pregnancy (28 weeks or more of gestation)will collect a random sample of urine for a spot test (protein/creatinine ratio) and urine for 24 hours. The level of proteinuria will be determined in this sample.

Other: Hypertensive disorder of pregnancy

Interventions

Collection of a random sample of urine for a spot test and a 24 hour urine collection for a 24 hour urine protein.

Hypertensive disorder of pregnancy

Eligibility Criteria

Sexfemale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Pregnant women with 28 weeks or more of gestation.
  • Complete collection of the 24 hour urine sample.

You may not qualify if:

  • Failure to recollect the 24 hour urine sample.
  • Pregestational Diabetes
  • Kidney disease
  • hour urine protein \> 8.0 g/dL or seric creatinine \> 2.0 mg/dL (it could indicate kidney disease).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Saint Thomas H

Panama City, Panama

Location

MeSH Terms

Conditions

Hypertension, Pregnancy-InducedHypertension

Condition Hierarchy (Ancestors)

Pregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesVascular DiseasesCardiovascular Diseases

Study Officials

  • Osvaldo A Reyes, MD

    Saint Thomas Hospital, Panama

    PRINCIPAL INVESTIGATOR
  • Joanna Buitrago, MD

    Saint Thomas Hospital, Panama

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Coordinator of Research & Development

Study Record Dates

First Submitted

January 8, 2012

First Posted

January 11, 2012

Study Start

March 1, 2012

Primary Completion

June 1, 2016

Study Completion

July 1, 2016

Last Updated

January 4, 2018

Record last verified: 2018-01

Locations